BACKGROUND: Although comorbid substance misuse is common in alcohol dependence, and polysubstance abusers (PSU) represent the largest group of individuals seeking treatment for drug abuse today, we know little about potential brain abnormalities in this population. Brain magnetic resonance spectroscopy studies of mono-substance use disorders (e.g., alcohol or cocaine) reveal abnormal levels of cortical metabolites (reflecting neuronal integrity, cell membrane turnover/synthesis, cellular bioenergetics, gliosis) and altered concentrations of glutamate and γ-aminobutyric acid (GABA). The concurrent misuse of several substances may have unique and different effects on brain biology and function compared to any mono-substance misuse. METHODS: High field brain magnetic resonance spectroscopy at 4 T and neurocognitive testing were performed at one month of abstinence in 40 alcohol dependent individuals (ALC), 28 alcohol dependent PSU and 16 drug-free controls. Absolute metabolite concentrations were calculated in anterior cingulate (ACC), parieto-occipital (POC) and dorso-lateral prefrontal cortices (DLPFC). RESULTS: Compared to ALC, PSU demonstrated significant metabolic abnormalities in the DLPFC and strong trends to lower GABA in the ACC. Metabolite levels in ALC and light drinking controls were statistically equivalent. Within PSU, lower DLPFC GABA levels are related to greater cocaine consumption. Several cortical metabolite concentrations were associated with cognitive performance. CONCLUSIONS: While metabolite concentrations in ALC at one month of abstinence were largely normal, PSU showed persistent and functionally significant metabolic abnormalities, primarily in the DLPFC. Our results point to specific metabolic deficits as biomarkers in polysubstance misuse and as targets for pharmacological and behavioral PSU-specific treatment.
BACKGROUND: Although comorbid substance misuse is common in alcohol dependence, and polysubstance abusers (PSU) represent the largest group of individuals seeking treatment for drug abuse today, we know little about potential brain abnormalities in this population. Brain magnetic resonance spectroscopy studies of mono-substance use disorders (e.g., alcohol or cocaine) reveal abnormal levels of cortical metabolites (reflecting neuronal integrity, cell membrane turnover/synthesis, cellular bioenergetics, gliosis) and altered concentrations of glutamate and γ-aminobutyric acid (GABA). The concurrent misuse of several substances may have unique and different effects on brain biology and function compared to any mono-substance misuse. METHODS: High field brain magnetic resonance spectroscopy at 4 T and neurocognitive testing were performed at one month of abstinence in 40 alcohol dependent individuals (ALC), 28 alcohol dependent PSU and 16 drug-free controls. Absolute metabolite concentrations were calculated in anterior cingulate (ACC), parieto-occipital (POC) and dorso-lateral prefrontal cortices (DLPFC). RESULTS: Compared to ALC, PSU demonstrated significant metabolic abnormalities in the DLPFC and strong trends to lower GABA in the ACC. Metabolite levels in ALC and light drinking controls were statistically equivalent. Within PSU, lower DLPFC GABA levels are related to greater cocaine consumption. Several cortical metabolite concentrations were associated with cognitive performance. CONCLUSIONS: While metabolite concentrations in ALC at one month of abstinence were largely normal, PSU showed persistent and functionally significant metabolic abnormalities, primarily in the DLPFC. Our results point to specific metabolic deficits as biomarkers in polysubstance misuse and as targets for pharmacological and behavioral PSU-specific treatment.
Authors: Krista Lisdahl Medina; Paula K Shear; John Schafer; Tisha Gangopadhyay Armstrong; Patrick Dyer Journal: Arch Clin Neuropsychol Date: 2004-03 Impact factor: 2.813
Authors: B C Schweinsburg; M J Taylor; O M Alhassoon; J S Videen; G G Brown; T L Patterson; F Berger; I Grant Journal: Alcohol Clin Exp Res Date: 2001-06 Impact factor: 3.455
Authors: Karen D Ersche; Anna Barnes; P Simon Jones; Sharon Morein-Zamir; Trevor W Robbins; Edward T Bullmore Journal: Brain Date: 2011-06-20 Impact factor: 13.501
Authors: James J Prisciandaro; Joseph P Schacht; Andrew P Prescot; Perry F Renshaw; Truman R Brown; Raymond F Anton Journal: Alcohol Clin Exp Res Date: 2019-01-04 Impact factor: 3.455
Authors: Anderson Mon; Timothy C Durazzo; Christoph Abe; Stefan Gazdzinski; David Pennington; Thomas Schmidt; Dieter J Meyerhoff Journal: Drug Alcohol Depend Date: 2014-09-19 Impact factor: 4.492
Authors: Andrew C Young; Constantin T Yiannoutsos; Manu Hegde; Evelyn Lee; Julia Peterson; Rudy Walter; Richard W Price; Dieter J Meyerhoff; Serena Spudich Journal: Neurology Date: 2014-09-26 Impact factor: 9.910
Authors: James J Prisciandaro; Joseph P Schacht; Andrew P Prescot; Helena M Brenner; Perry F Renshaw; Truman R Brown; Raymond F Anton Journal: Addict Biol Date: 2019-08-01 Impact factor: 4.280